Consolidated Balance Sheets (Unaudited) - USD ($) $ in Thousands	Mar. 31, 2023	Dec. 31, 2022
Current assets:
Cash and cash equivalents	$ 37,655	$ 23,634
Marketable investments	12,662	26,344
Accounts receivables, net	26,524	24,469
Inventory	11,308	9,976
Prepaid expenses	7,827	8,807
Other current assets	4,784	3,143
Total current assets	100,760	96,373
Property and equipment, net	54,861	51,971
Operating lease right-of-use assets	85,398	86,464
Intangibles, net	123,875	136,902
Goodwill	80,269	80,269
Equity investments	12,008	17,176
Other assets, net	2,892	3,685
Total assets	460,063	472,840
Current liabilities:
Accounts payable	14,590	47,515
Accrued payroll and related benefits	5,314	7,884
Accrued expenses and other current liabilities	68,855	58,456
Accrued legal settlements		174,752
Current portion of deferred revenue	252	652
Current portion of operating lease liabilities	14,050	13,880
Current portion of contingent consideration	397	397
Acquisition consideration	391	7,800
Income tax payable	12,148	300
Current portion of debt	49,635	16,286
Total current liabilities	165,632	327,922
Long-term debt, net of discount	21,400	19,130
Deferred tax liabilities, net	238	591
Deferred revenue	983	7,098
Derivative liabilities	1,580	300
Operating lease liabilities	84,462	85,208
Contingent consideration	550	48,949
Other long-term liabilities	3,428	5,311
Total liabilities not subject to compromise	278,273	494,509
Liabilities subject to compromise	309,210
Total liabilities	587,483	494,509
Commitments and contingencies (See Note 10)
Sorrento Therapeutics, Inc. equity (deficit)
Common stock, $0.0001 par value 750,000,000 shares authorized and 551,281,154 and 522,817,137 shares issued and outstanding at March 31, 2023 and December 31, 2022, respectively	55	52
Additional paid-in capital	2,021,148	1,988,753
Accumulated other comprehensive income	1,826	1,501
Accumulated deficit	(2,099,063)	(1,959,447)
Treasury stock, 7,568,182 shares at cost at March 31, 2023, and December 31, 2022	(49,464)	(49,464)
Total Sorrento Therapeutics, Inc. stockholders' equity (deficit)	(125,498)	(18,605)
Noncontrolling interests	(1,922)	(3,064)
Total equity (deficit)	(127,420)	(21,669)
Total liabilities and stockholders' equity (deficit)	$ 460,063	$ 472,840